Form 4: IGM Biosciences Director Michael Lee Receives Stock as Quarterly Retainer

Director Michael Lee of IGM Biosciences reports the acquisition of 828 shares of common stock as a quarterly retainer, held on behalf of Redmile Group, LLC.

Summary

• Michael Lee, a director of IGM Biosciences, filed a Form 4 disclosing a transaction on March 31, 2025.
• Lee acquired 828 shares of IGM Biosciences common stock as a quarterly retainer, valued at $0.00 per share.
• These shares are fully vested restricted stock units, each representing a right to receive one share of IGM Biosciences common stock.
• Following the transaction, Lee directly owns 11,884 shares of IGM Biosciences common stock.
• Lee is a managing director of Redmile Group, LLC and holds the securities as a nominee for Redmile, assigning all economic and voting rights to them.
• Lee disclaims beneficial ownership of the securities, and the filing is not an admission of beneficial ownership.
• Jeremy Green, as principal of Redmile, may also be deemed a beneficial owner, but disclaims ownership except for pecuniary interest.
• Lee was elected to the board as a representative of Redmile and its affiliates, making Redmile and Green directors by deputization.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The director's stock acquisition is a positive sign, but the disclaimer of beneficial ownership introduces a layer of complexity.

Positives

• The acquisition of shares by a director, even as a retainer, can signal confidence in the company.
• The shares are fully vested restricted stock units, indicating a long-term commitment.

Risks

• The director disclaims beneficial ownership, indicating the shares are primarily for the benefit of Redmile Group, LLC, which could influence voting decisions.
• The filing mentions potential beneficial ownership by Jeremy Green, which could lead to concentrated control.

Future Outlook

The document does not contain specific forward-looking statements, but the ongoing compensation in stock suggests continued involvement of the director and Redmile Group with IGM Biosciences.

Management Comments

• Mr. Lee disclaims beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors. The arrangement with Redmile Group is not uncommon, where investment firms have board representation and receive compensation in stock.

Comparison to Industry Standards

• Director compensation in the form of stock is a common practice in the biotechnology industry, aligning the interests of directors with shareholders.
• Redmile Group's involvement as a significant shareholder and board representative is similar to other investment firms that take active roles in portfolio companies.
• The disclaimer of beneficial ownership by the director is a standard legal precaution when shares are held on behalf of a larger entity.

Related Party Transactions

• The transaction involves a related party, Michael Lee, a director of IGM Biosciences, and Redmile Group, LLC, where Lee is a managing director. The stock is held on behalf of Redmile as part of Lee's compensation for serving on the board.

Stakeholder Impact

• Shareholders may view the stock acquisition as a positive sign of alignment between management and shareholder interests.
• The arrangement with Redmile Group could influence corporate decisions, potentially impacting other stakeholders.

Key Dates

Keywords

IGM Biosciences, Director, Michael Lee, Redmile Group, Stock Acquisition, Form 4, Beneficial Ownership, Restricted Stock Units